ShiraTronics Reaches Key Milestones in Pivotal Study for Chronic Migraine Treatment

ShiraTronics, Inc., a clinical-stage medical device company, has recently achieved significant milestones in its ongoing trial for a groundbreaking treatment aimed at chronic migraine sufferers. The company's investigational device, part of the new category of Implantable Extracranial Neuromodulation Systems (IENs), has successfully completed enrollment in the RELIEV-CM2 pivotal trial, a critical step towards regulatory approval and commercialization.

Pivotal Trial Enrollment Completion

The RELIEV-CM2 study is designed to evaluate the safety and efficacy of the ShiraTronics system among adults experiencing chronic migraines. Over a span of 18 months, enrollment was completed across 28 clinical sites in the U.S. and Australia, with 300 participants signed up for the trial. Notably, 146 of these individuals have already received the investigational device implant. This swift enrollment reflects not just the importance of the trial but also the pressing demand for innovative solutions to treat chronic migraines—a condition that has historically been challenging to address.

CEO Rob Binney expressed gratitude towards all the patients, investigators, and study teams involved, emphasizing that the significant pace of enrollment signifies a real need for new treatment options. This sentiment is echoed by the American Medical Association (AMA), which recently accepted an exclusive set of five Category III CPT codes for the procedure. The establishment of these codes is crucial and represents the recognition of a new procedural category distinct from previous treatments available.

Importance of the CPT Code Acceptance

The AMA's acknowledgment of the procedure through these categories not only highlights its unique status but also ensures that it is officially recognized within clinical practices. While these CPT codes do not automatically guarantee coverage or payment, they signal a noteworthy early recognition of IENs as an emerging treatment option. Joshua Rosenow, MD, a neurosurgeon and investigator in the RELIEV-CM2 trial, stated that receiving dedicated codes reflects that the procedure is new and deserving of its own classification, which carries significant weight in the medical community.

Positive Outcomes from Prior Study

These milestones follow promising findings from the earlier RELIEV-CM Pilot Study, which indicated substantial reductions in monthly headache days and improvements in quality of life for participants using the investigational device. The results thus far support a favorable safety profile for the ShiraTronics system, further validating the need for this innovative treatment.

ShiraTronics Device and Future Expectations

The ShiraTronics system is a fully implantable device targeting the trigeminal nerve complex, which plays a critical role in migraines. Its unique continuous delivery of neurostimulation therapy offers a novel approach to proactively prevent migraines, contrasting with existing options that often require active management once an attack starts.

As the completion of enrollment brings the trial closer to its planned data readout, ShiraTronics is gearing up to pursue Premarket Approval (PMA) with the FDA. This regulatory pathway is vital for commercial launch, which is projected to occur shortly after the conclusion of clinical evaluation and regulatory assessment.

ShiraTronics’ drive to innovate in the field of chronic migraine treatment comes at a time when many patients are seeking alternatives to existing therapies. The company has invested significantly in research and development, having raised over $108 million to date, showcasing its commitment to setting a new standard for migraine management. The anticipated outcomes of this pivotal trial could pave the way for a new era of treatment options for the millions who suffer from chronic migraines.

In summary, ShiraTronics is at a pivotal moment in its mission to help those struggling with chronic migraines. The completion of pivotal trial enrollment and recognition from the AMA lay a strong foundation for future advancements, potentially transforming the landscape of treatment options available to patients worldwide.